Kumamoto, Japan

Kazuhiko Kimachi

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 60(Granted Patents)


Location History:

  • Kikuchi-gun, JP (1997)
  • Kyo, JP (1998)
  • Kumamoto, JP (1996 - 2021)
  • Kikuchi, JP (2012 - 2021)

Company Filing History:


Years Active: 1996-2021

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Kazuhiko Kimachi: Innovator in Vaccine Development

Introduction

Kazuhiko Kimachi is a prominent inventor based in Kumamoto, Japan. He has made significant contributions to the field of vaccine development, holding a total of 13 patents. His work focuses on improving the stability and efficacy of vaccines, particularly those related to Hib (Haemophilus influenzae type b).

Latest Patents

Among his latest patents, Kimachi has developed a method for producing a Hib conjugate vaccine using PRP (polyribosylribitol phosphate) with lowered molecular weight. This innovative method enhances the storage stability of the vaccine while maintaining sufficient immunogenicity. Additionally, he has created a vaccine containing immobilized virus particles, which demonstrates a reduced fever response in test subjects, indicating a safer profile for vaccine administration.

Career Highlights

Throughout his career, Kimachi has worked with notable organizations such as the Chemo-Sero-Therapeutic Research Institute and Km Biologics Co., Ltd. His expertise in vaccine technology has positioned him as a key figure in the development of effective immunization strategies.

Collaborations

Kimachi has collaborated with esteemed colleagues, including Hiroaki Maeda and Sachio Tokiyoshi. These partnerships have furthered his research and contributed to advancements in vaccine technology.

Conclusion

Kazuhiko Kimachi's innovative work in vaccine development has led to significant advancements in the field, particularly in enhancing the stability and safety of vaccines. His contributions continue to impact public health positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…